New hope for PNH patients: drug shows promise in early trial
NCT ID NCT05972967
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 27 times
Summary
This study tested a new drug called OMS906 in 12 adults with PNH, a rare blood disease, who were not getting enough benefit from the standard treatment ravulizumab. The goal was to see if OMS906 is safe and can raise hemoglobin levels. Participants received OMS906 every 8 weeks, and researchers monitored side effects and blood improvements.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Omeros Investigational Site
Aachen, Germany
-
Omeros Investigational Site
Ulm, Germany
-
Omeros Investigational Site
Thessaloniki, Greece
-
Omeros Investigational Site
Lausanne, Switzerland
-
Omeros Investigational Site
Leeds, United Kingdom
Conditions
Explore the condition pages connected to this study.